ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

Scientifically-designed fasting diet lowers risks for major diseases

How One Tiny Molecule Turned into One Huge Health Breakthrough

Acupuncture boosts effectiveness of standard medical care for chronic pain, depression

Research on Astaxanthin Demonstrates Significant Whole Body Benefits

Humans have three times more brown body fat

Nutrients Boost Stem Cell Function

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

Dietary prebiotics improve sleep, buffer impacts of stress, says study

 
Print Page
Email Article

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial - Source: Lancet, Aug 2008

  [ 22 votes ]   [ Discuss This Article ]
By Paul Emery, et al. • www.ProHealth.com • August 25, 2008


Background: Remission and radiographic non-progression are goals in the treatment of early rheumatoid arthritis. The aim of the combination of methotrexate and etanercept in active early rheumatoid arthritis (COMET) trial is to compare remission and radiographic non-progression in patients treated with methotrexate monotherapy or with methotrexate plus etanercept.

[Note: ‘Clinical remission’ is defined as absence of clinical signs of inflammation. Radiographic non-progression is determined by a Sharp score – an X-ray measurement of changes in total joint damage as assessed by bone erosion & joint space narrowing.]

Methods: 542 outpatients who were methotrexate-naive and had had early moderate-to-severe rheumatoid arthritis for 3 to 24 months were randomly assigned to receive either methotrexate alone titrated up from 7.5 mg a week to a maximum of 20 mg a week by week 8 or methotrexate (same titration) plus etanercept 50 mg a week.

Coprimary endpoints at 52 weeks were remission measured with the disease activity score in 28 joints (DAS28) and radiographic non-progression measured with modified total Sharp score.

Treatment was allocated with a computerized randomization and enrollment system, which masked both participants and carers. Analysis was done by modified intention to treat with last observation carried forward for missing data. This study is registered with ClinicalTrials.gov, number NCT00195494.

Findings: 274 participants were randomly assigned to receive combined treatment, and 268 methotrexate alone.

  • 132 of 265 (50%, 95% CI 44-56%) patients who took combined treatment and were available for assessment achieved clinical remission
  • Compared with 73 of 263 (28%, 23-33%) taking methotrexate alone (effect difference 22.05%, 95%CI 13.96-30.15%, p<0.0001) [Probability that finding resulted by chance less than 1 in 10,000.]

487 evaluable patients had severe disease (DAS28>5.1).

196 of 246 (80%, 75-85%) and 135 of 230 (59%, 53-65%), respectively, achieved radiographic non-progression (20.98%, 12.97-29.09%, p<0.0001).

Serious adverse events were similar between groups.

Interpretation: Both clinical remission and radiographic non-progression are achievable goals in patients with early severe rheumatoid arthritis within 1 year of combined treatment with etanercept plus methotrexate.

Funding: Wyeth Research.

Source: Lancet, Aug 2, 2008; 372(9636):375-82. PMID: 18635256, by Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Leeds Institute of Molecular Medicine, University of Leeds, Leeds Teaching Hospitals Trust, Chapel Allerton Hospital, Leeds, UK. [E-mail: p.emery@leeds.ac.uk]





Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Thyroid Health and Fibromyalgia Thyroid Health and Fibromyalgia

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map